BioCentury | Oct 30, 2006
Product Development

Trail of tearst

...2000, missed primary endpoint in Ph III ischemic stroke trial, although hit some secondary endpoints Cambridge NeuroScience/...
BioCentury | Dec 10, 2001
Clinical News

Cerestat aptiganel: Phase III results; discontinued

...product was not efficacious (see BioCentury, Sept. 22, Dec. 22, 1997). Cerestat was developed by Cambridge Neuroscience Inc....
BioCentury | Feb 20, 2001
Finance

Ebb & Flow

...The fund became a holder in CEN after the drug delivery and neurological company acquired Cambridge NeuroScience...
...late last year (see BioCentury, Jan. 2). City talk suggested that BVF originally bought into Cambridge NeuroScience...
BioCentury | Feb 20, 2001
Finance

Ebb & Flow

...The fund became a holder in CEN after the drug delivery and neurological company acquired Cambridge NeuroScience...
...late last year (see BioCentury, Jan. 2). City talk suggested that BVF originally bought into Cambridge NeuroScience...
BioCentury | Jan 16, 2001
Company News

CeNeS other research news

...CEN subsidiary Cambridge NeuroScience Inc. (Cambridge, Mass.) received a $860,000 Phase II SBIR grant from the National Institute...
BioCentury | Jan 2, 2001
Company News

Cambridge NeuroScience, CeNeS deal

...merged company will focus on central nervous system disorders and pain control. (CEN/Shire deal, Below) Cambridge NeuroScience Inc....
BioCentury | Nov 6, 2000
Strategy

Building a franchise

...Building a franchise Company Deal GlaxoWellcome CEN acquired 3 pain products Cambridge Neuroscience CEN acquired ion channel...
BioCentury | Nov 6, 2000
Strategy

CeNeS hurries to grow

...is the best way to grow. Along those lines, CEN is completing its acquisition of Cambridge Neuroscience Inc....
BioCentury | Jul 17, 2000
Company News

Cambridge NeuroScience other research news

...company's Glial Growth Factor 2 ( GGF2 ), which is encoded by the Neuregulin-1 gene. Cambridge NeuroScience Inc....
BioCentury | Jun 12, 2000
Finance

Ebb & Flow

...closed Friday at $30.50 . . . Chap-Cap Partners and affiliates purchased 225,000 shares of Cambridge NeuroScience...
Items per page:
1 - 10 of 86
BioCentury | Oct 30, 2006
Product Development

Trail of tearst

...2000, missed primary endpoint in Ph III ischemic stroke trial, although hit some secondary endpoints Cambridge NeuroScience/...
BioCentury | Dec 10, 2001
Clinical News

Cerestat aptiganel: Phase III results; discontinued

...product was not efficacious (see BioCentury, Sept. 22, Dec. 22, 1997). Cerestat was developed by Cambridge Neuroscience Inc....
BioCentury | Feb 20, 2001
Finance

Ebb & Flow

...The fund became a holder in CEN after the drug delivery and neurological company acquired Cambridge NeuroScience...
...late last year (see BioCentury, Jan. 2). City talk suggested that BVF originally bought into Cambridge NeuroScience...
BioCentury | Feb 20, 2001
Finance

Ebb & Flow

...The fund became a holder in CEN after the drug delivery and neurological company acquired Cambridge NeuroScience...
...late last year (see BioCentury, Jan. 2). City talk suggested that BVF originally bought into Cambridge NeuroScience...
BioCentury | Jan 16, 2001
Company News

CeNeS other research news

...CEN subsidiary Cambridge NeuroScience Inc. (Cambridge, Mass.) received a $860,000 Phase II SBIR grant from the National Institute...
BioCentury | Jan 2, 2001
Company News

Cambridge NeuroScience, CeNeS deal

...merged company will focus on central nervous system disorders and pain control. (CEN/Shire deal, Below) Cambridge NeuroScience Inc....
BioCentury | Nov 6, 2000
Strategy

Building a franchise

...Building a franchise Company Deal GlaxoWellcome CEN acquired 3 pain products Cambridge Neuroscience CEN acquired ion channel...
BioCentury | Nov 6, 2000
Strategy

CeNeS hurries to grow

...is the best way to grow. Along those lines, CEN is completing its acquisition of Cambridge Neuroscience Inc....
BioCentury | Jul 17, 2000
Company News

Cambridge NeuroScience other research news

...company's Glial Growth Factor 2 ( GGF2 ), which is encoded by the Neuregulin-1 gene. Cambridge NeuroScience Inc....
BioCentury | Jun 12, 2000
Finance

Ebb & Flow

...closed Friday at $30.50 . . . Chap-Cap Partners and affiliates purchased 225,000 shares of Cambridge NeuroScience...
Items per page:
1 - 10 of 86